These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8709183)

  • 1. [Clinical manifestations and effects of IVGG in patients with Kawasaki disease].
    Hwang KP; Wu JR; Huang LY; Liou CC; Huang TY
    Kaohsiung J Med Sci; 1996 Mar; 12(3):159-66. PubMed ID: 8709183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on coronary artery lesions in patients with Kawasaki disease: recent 9 years' experience].
    Wu JR; Hwang KP; Tu JG; Dai ZK; Huang TY
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1993 Jan; 9(1):27-38. PubMed ID: 7682261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
    Terai M; Shulman ST
    J Pediatr; 1997 Dec; 131(6):888-93. PubMed ID: 9427895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.
    Hsu CH; Chen MR; Hwang FY; Kao HA; Hung HY; Hsu CH
    Pediatr Infect Dis J; 1993 Jun; 12(6):509-12. PubMed ID: 8345983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous gamma-globulin for Kawasaki disease.
    Furusho K; Kamiya T; Nakano H; Kiyosawa N; Shinomiya K; Hayashidera T; Tamura T; Hirose O; Manabe Y; Yokoyama T
    Acta Paediatr Jpn; 1991 Dec; 33(6):799-804. PubMed ID: 1801560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Kawasaki disease in the British Isles.
    Dhillon R; Newton L; Rudd PT; Hall SM
    Arch Dis Child; 1993 Dec; 69(6):631-6; discussion 637-8. PubMed ID: 8285773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose intravenous gammaglobulin for Kawasaki disease.
    Furusho K; Kamiya T; Nakano H; Kiyosawa N; Shinomiya K; Hayashidera T; Tamura T; Hirose O; Manabe Y; Yokoyama T
    Lancet; 1984 Nov; 2(8411):1055-8. PubMed ID: 6209513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
    Furukawa S; Matsubara T; Umezawa Y; Motohashi T; Ino T; Yabuta K
    Eur J Pediatr; 1994 Sep; 153(9):663-7. PubMed ID: 7957426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N; Sugimura T; Akagi T; Yamakawa R; Hashino K; Eto G; Iemura M; Ishii M; Kato H
    Pediatr Int; 1999 Feb; 41(1):1-7. PubMed ID: 10200128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kawasaki disease in infants less than one year of age.
    Rosenfeld EA; Corydon KE; Shulman ST
    J Pediatr; 1995 Apr; 126(4):524-9. PubMed ID: 7699529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
    Muta H; Ishii M; Egami K; Furui J; Sugahara Y; Akagi T; Nakamura Y; Yanagawa H; Matsuishi T
    J Pediatr; 2004 Apr; 144(4):496-9. PubMed ID: 15069399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive risk factors for coronary artery abnormalities in Kawasaki disease.
    Kim T; Choi W; Woo CW; Choi B; Lee J; Lee K; Son C; Lee J
    Eur J Pediatr; 2007 May; 166(5):421-5. PubMed ID: 17033807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of vascular leakage in acute Kawasaki disease.
    Terai M; Honda T; Yasukawa K; Higashi K; Hamada H; Kohno Y
    Circulation; 2003 Jul; 108(3):325-30. PubMed ID: 12835221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of atypical Kawasaki disease.
    Hsieh YC; Wu MH; Wang JK; Lee PI; Lee CY; Huang LM
    J Microbiol Immunol Infect; 2002 Mar; 35(1):57-60. PubMed ID: 11950122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
    Saulsbury FT
    Clin Pediatr (Phila); 2002 Oct; 41(8):597-601. PubMed ID: 12403377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of pharmacological treatment of Kawasaki disease.
    Onouchi Z; Kawasaki T
    Drugs; 1999 Nov; 58(5):813-22. PubMed ID: 10595862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.